Early Bellwether Trials Set the Stage for Hundreds of Other Xarelto Claims

Ten to fifteen percent of the 400 pending Xarelto bleeding lawsuits will soon be selected as the initial group of cases to proceed forward to discovery and trial. These bellwether suits will be the first to test evidence and arguments in front of a jury, providing insight into the totality of claims against Bayer and Johnson & Johnson over its dangerous anticoagulant, which lacks a reversal agent for uncontrollable bleeding. The result of these cases often helps determine appropriate compensation levels for victims in a potential future settlement of all claims, as was the case in the $650 million Pradaxa settlement.

Real Time Analytics